Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing